Siemens Healthineers AG Stock Timeline

TickerSHL.XETRA
Current Price –
Siemens Healthineers AG – stock chart

Five-year timeline for Siemens Healthineers AG (SHL.XETRA): major events, developments and context behind the stock's recent history.

View full stock analysis →

5-year stock timeline

2026 — Q3 FY2026 results; updated FY2026 outlook

Siemens Healthineers reported Q3 FY2026 results (April 1–June 30, 2026) with strong equipment order momentum (book-to-bill 1.27) offset by Diagnostics weakness, particularly in China. Tariff refunds in the U.S. raised EPS guidance while revenue-growth guidance was lowered. Management reduced the FY2026 comparable revenue-growth range to 3.5%–4.0% due to persistent Diagnostics headwinds, and raised adjusted basic EPS guidance to €2.35–€2.45 (from €2.20–€2.30) on the back of tariff refunds.

The market read mixed signals in the results. Very healthy order intake and margin support from one-off tariff refunds improved near-term earnings credibility, yet persistent Diagnostics headwinds and a lower revenue guide kept concerns about organic growth and China exposure alive. The stock narrative shifted to "resilient operational momentum with structural diagnostic headwinds," with emphasis on Precision Therapy and Varian as the growth offset.

Q3 FY2026 revenue reached €5,764m with adjusted EBIT margin around 19.1%. Adjusted basic EPS for the quarter was €0.70. Equipment book-to-bill stood at 1.27 [3][1].

2025 (fiscal year) — Post-Varian integration and midterm targets reaffirmed

After Varian acquisition integration continued through FY2025, Siemens Healthineers emphasized synergies and the strategic role of Varian and Precision Therapy in driving medium-term growth and margins. Management reiterated midterm ambitions including double-digit EPS progression.

Market perception transitioned from acquisition risk to a growth and upgrade story as Varian contributed recurring revenue and expanded the company's oncology footprint. Investors began valuing the company more on combined Imaging and Precision Therapy dynamics rather than Diagnostics alone.

Management had targeted at least €300m per annum in EBIT synergies from Varian by fiscal 2025 and reported improving contribution from Precision Therapy businesses in FY2025 commentary [14][13].

2024 — Ongoing Varian integration and segment reporting changes

Siemens Healthineers continued integrating Varian into its group structure as a distinct business within the Precision Therapy and oncology area. The company executed product launches and commercial rollouts for Varian platforms and emphasized cross-selling with Imaging and Diagnostics.

Investors increasingly treated Healthineers as a combined diagnostic-to-therapy platform with stronger long-term growth optionality. Near-term integration costs and execution risk were monitored, yet the strategic rationale of end-to-end cancer care supported a re-rating narrative for many shareholders.

Company statements described Varian as a new business segment following the 2021 closing and reported contribution to group adjusted EPS within the first 12 months after closing. Investor materials documented revenue and margin contributions by segment, with Precision Therapy growth outpacing Diagnostics in several quarters [14][8].

2022–2023 — Diagnostics weakness (China) and COVID-era demand normalization

Siemens Healthineers' Diagnostics segment experienced demand weakness and structural market changes in China and other regions during this period. Post-pandemic normalization in lab-testing volumes and competitive pressures affected Diagnostics revenue growth. Management adjusted segment commentary and guided for recovery over time while focusing investment in higher-margin Imaging and Precision Therapy.

Investor perception bifurcated: Diagnostics was viewed as a near-term headwind and potential value-trap area, while Imaging and the recently acquired Varian (Precision Therapy) were framed as the recovery and growth engines. The stock narrative emphasized portfolio rebalancing toward higher-growth, higher-margin businesses.

Company disclosures across FY2022–FY2023 quarterly and annual reports noted comparable revenue declines in Diagnostics in certain quarters and referenced Chinese market headwinds. Investors tracked segment comparable growth rates in quarterly reporting, with Diagnostics showing negative comparables versus Imaging and Precision Therapy growth [3][8].

2021 — Completion of Varian acquisition (transformative M&A)

Siemens Healthineers completed the acquisition of Varian Medical Systems on April 15, 2021 (announced August 2020). Varian became a new business segment, intended to create an end-to-end oncology franchise spanning imaging, diagnostics, and therapy, with an ambition to deliver at least €300m per annum in EBIT synergies by fiscal 2025. Management presented the deal as a centerpiece of Strategy 2025 ("Upgrading").

The market treated the deal as transformative, shifting Siemens Healthineers' identity from a diagnostics and imaging vendor toward an integrated cancer-care platform. Early investor debate centered on integration risk, purchase-price allocation, and near-term dilution versus the long-term strategic upside and cross-selling potential. Over time the narrative moved toward valuation on combined earnings power if synergies and cross-sell materialized.

The stated ambition was that Varian would positively contribute to adjusted basic EPS within the first 12 months and deliver at least €300m per annum in EBIT synergies by FY2025 [14].

Get More Stock Analyses Like This

Receive hand-picked stock recommendations with detailed analyses every week

Start Free Trial
© Leeway
PWP Leeway UG (haftungsbeschränkt)
Leeway Icon